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Hydroxysteroid 17- dehydrogenase 13 (HSD17B13) is a lipid droplet–associated protein; its 
gene-encoding variants affect the chronic liver diseases, including nonalcoholic fatty liver 
disease (NAFLD). To estimate the effect of rs72613567, a splice variant with an adenine 
insertion (A-INS), on NAFLD susceptibility and severity, we performed a case-control study 
with 609 individuals. We investigated the effect of carrying the A-INS allele in 356 patients 
with biopsy-proven disease and explored the relationship between rs72613567genotypes and 
the hepatic transcriptome. The A-INS allele protected against NAFLD (odds ratio [OR] per A 
allele = 0.667; 95% CI, 0.486−0.916;P=0.012); this effect was non significant when logistic 
regression analysis included body mass index. The A-INS allele protected against 
nonalcoholic steatohepatitis (NASH; OR = 0.612; 95% CI, 0.388−0.964;P=0.033), 
ballooning degeneration (OR = 0.474; 95% CI, 0.267−0.842; P = 0.01), lobular inflammation 
(OR = 0.475; 95% CI, 0.275−0.821; P = 0.007), and fibrosis (OR = 0.590; 95% CI, 
0.361−0.965; P = 0.035). In patients carrying A-INS, HSD17B13 levels decreased 
proportional to allele dosage. Whole-transcriptome genotype profiling showed 
overrepresented immune response–related pathways. Thus, the rs72613567 A-INS allele 
reduces the risk of NASH and progressive liver damage and may become a therapeutic target. 
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Nonalcoholic fatty liver disease (NAFLD), which affects a high proportion of the global adult 
and child population, has emerged as the leading cause of end-stage liver disease (1;2). A 
growing body of evidence indicates that NAFLD is a heritable (3) and polygenic complex 
trait (4). Variants located in genes that regulate lipid metabolism and lipid droplet biology, 
including PNPLA3-rs738409 and TM6SF2-rs58542926 have been consistently replicated as 
major modifiers of the natural history of NAFLD (5-8), increasing the risk of developing 
severe histological forms of the disease, such as nonalcoholic steatohepatitis (NASH) and 
NASH-fibrosis. Of note, variants—more specifically single nucleotide polymorphisms 
(SNPs)—in the aforementioned genes have been discovered as a part of genome-wide (5) or 
exome-wide (7) association studies. Likewise, recent remarkable results from exome-
sequence data coupled with electronic health-records of 46,455 participants uncovered the 
association of the rs72613567 (-/A) deletion/insertion (INS)-variant in HSD17B13 
(hydroxysteroid 17-beta dehydrogenase 13) with a reduced risk of chronic liver disease, 
including NASH (9). Research findings further indicate that the rs72613567 variant is 
reproducibly associated with decreased ALT (alanine aminotransferase) and AST (aspartate 
aminotransferase) serum levels (9).  
HSD17B13 encodes a protein that is involved in the regulation of lipid biosynthetic process 
(10); molecular analysis (11) and recent proteomic studies (10) have identified HSD17B13 as 
a novel liver lipid-droplet associated protein. 
Findings yielded by recent functional studies demonstrate that the rs72613567—regarded as a 
splice region variant—is indeed a loss-of-function variant, which consists of an adenine (A) 
insertion in the coding gene region (chr4:87310241, GRCh38.p7) adjacent to the donor splice 
site of exon 6 that results in a frame-shift and premature truncation of the HSD17B13 protein 
(9).  













Of note, the protective effect of the rs72613567 A-INS allele against NASH was recently 
observed in a sample of morbidly obese patients recruited from a bariatric cohort (9). As a 
part of the same study, the original description of the protective effect of the rs72613567-
insertion variant on chronic liver damage was examined in a population of European 
Americans among whom the A-INS frequency is ~24% (9). Therefore, it remains to be 
established whether the observed influential effect of the variant on the course of NAFLD can 
be generalised to other populations. Hence, we explored the association between rs72613567 
and NAFLD disease severity, including a putative protecting effect on histological features 
associated with progressive damage. Furthermore, we aimed to explore the impact of carrying 
the rs72613567 A-INS allele in abundance and cell localisation of the HSD17B13 protein in 
the liver of the affected patients. To gain further biological insight into the role of 
rs72613567, we also explored differentially expressed genes of the whole transcriptome 
according to the variant genotypes.   
METHODS 
Study design and patient selection 
We performed a case-control association study to estimate the effect of the rs72613567 
variant on the susceptibility of NAFLD; this study involved a sample of 609 unrelated 
individuals, including 429 patients with NAFLD and 180 control subjects. Associations with 
NAFLD severity, including histological features known to be related to an aggressive course, 
were explored in a sample of 356 patients that showed the whole spectrum of the disease 
(nonalcoholic fatty liver-NAFL, NASH, and NASH-fibrosis), and who had histopathological 
confirmation of NAFLD.  
Patients and controls were selected from hospital-based settings, including patients diagnosed 
with NAFLD and Metabolic Syndrome (MetS) (Hospital Abel Zubizarreta, Buenos Aires, 













Argentina) and morbidly obese patients that underwent bariatric surgery (Hospital de Alta 
Complejidad en Red ―El Cruce‖, Buenos Aires, Argentina).  
Inclusion criteria: Liver ultrasonographic (US) examination was the initial screening criteria 
for selecting the cases and controls in the group of individuals included in the study of 
NAFLD and MetS, and it was performed in all the participants. Patients who presented fatty 
liver on liver US were indicated a liver biopsy if they showed either abnormal liver enzymes 
or severe insulin resistance (HOMA-IR value greater than 3) as explained earlier (6). A liver 
biopsy was performed in 268 patients who met the criteria; patients that showed 
ultrasonographic features of liver steatosis plus persistently normal liver enzymes during 
twelve months of follow-up were not included in the histological evaluation. All morbidly 
obese patients that were included in this study (n = 121) had histological confirmation of 
either NAFLD or normal liver by a liver biopsy that was performed during bariatric surgery.   
Exclusion criteria: Secondary causes of steatosis, including alcohol abuse (≥ 30 g for men 
and ≥ 20 g for women, of alcohol daily), total parenteral nutrition, hepatitis B and hepatitis C 
virus infection, and the use of drugs known to precipitate steatosis were excluded. In 
addition, patients with any of the following diseases were excluded: autoimmune liver 
disease, metabolic liver disease, Wilson’s disease, and -1-antitrypsin deficiency. 
Control subjects that matched patients with NAFLD-MetS were selected from subjects 
attending our hospital for check-up purposes whose age and sex matched the NAFLD 
patients. In addition to the standard heath examination, all control individuals were subjected 
to a liver US examination. They were included in the study if they did not have evidence of 
fatty change or biochemical abnormalities. Furthermore, control subjects were confirmed not 
to have any of the features of the metabolic syndrome as defined by the National Cholesterol 
Education Program Adult Treatment Panel III and did not abuse alcohol.  













In the population of morbid obese patients, control subjects were obese patients who also 
underwent bariatric surgery and had not features of NAFLD demonstrated in the liver biopsy. 
Liver biopsies from all patients as well as DNA samples from white blood cells from all the 
subjects included in this study were obtained with written, informed consent in accordance 
with the Institutional Review Board-approved protocols. All the investigations performed in 
this study were conducted in accordance with the guidelines of the 1975 Declaration of 
Helsinki, as revised in 1993. 
Control subjects that matched patients with NAFLD-MetS were selected from subjects 
attending our hospital for check-up purposes whose age and sex matched the NAFLD 
patients. In addition to the standard heath examination, all control individuals were subjected 
to a liver US examination. They were included in the study if they did not have evidence of 
fatty change or biochemical abnormalities. Furthermore, control subjects were confirmed not 
to have any of the features of the metabolic syndrome as defined by the National Cholesterol 
Education Program Adult Treatment Panel III and did not abuse alcohol. In the population of 
morbid obese patients, control subjects were obese patients who also underwent bariatric 
surgery and had not features of NAFLD demonstrated in the liver biopsy. 
The case participants and controls subjects were consecutively selected during the same study 
period from the same population of patients attending the participant institutions of 
Argentina, and all of them share the same demographic characteristics (occupation, 
educational level, place of residence, and ethnicity).  
Physical, anthropometric, biochemical evaluation and histological assessment  
Health examinations included anthropometric measurements, a questionnaire on health-
related behaviours and biochemical determinations (see Supplemental information).  
The disease severity was assessed by liver biopsy that was performed before any intervention 
with ultrasound guidance and a modified 1.4-mm-diameter Menghini needle (Hepafix, Braun, 













Germany) on an outpatient basis or during bariatric surgery. All liver biopsies were evaluated 
by the same pathologist. A portion of each liver biopsy specimen was routinely fixed in 40 g/l 
formaldehyde (pH 7.4), embedded in paraffin, and stained with hematoxylin and eosin, 
Masson trichrome, and silver impregnation for reticular fibers. All the biopsies were at least 3 
cm in length and contained a minimum of 8 portal tracts. The degree of steatosis was 
assessed according to the system developed by Kleiner et al., based on the percentage of 
hepatocytes containing macrovesicular fat droplets (12). NASH and NAFLD Activity Score 
(NAS) (12;13) were defined as reported previously, and a NAS threshold of 5 was used for 
further comparisons with variables of interest; NASH was defined as steatosis plus mixed 
inflammatory-cell infiltration, hepatocyte ballooning and necrosis, Mallory’s hyaline, and any 
stage of fibrosis, including absent fibrosis (12;13).  
Intra-acinar (lobular) inflammation was defined as the presence of cellular components of 
inflammation (polymorphonuclear leukocytes, lymphocytes and other mononuclear cells, 
eosinophils and microgranulomas) located in sinusoidal spaces, surrounding Mallory’s 
hyaline or in hepatocellular necrosis (1;13). It was graded 0–3 and was defined as 0 (absent) 
= no foci; 1 = < 2 foci per 200 × field; 2 = 2 to 4 foci per 200 × field; and 3 = >4 foci per 200 
× field. Ballooning was scored as: 0 = none; 1 = rare or few; and 2 = many (12;13). The 
severity of fibrosis was expressed on a 4-point scale, as follows: 0 = none; 1 = perivenular 
and/or perisinusoidal fibrosis in zone 3; 2 = combined pericellular portal fibrosis; 3 = septal/ 
bridging fibrosis; and 4 = cirrhosis (12;13). 
Genetic analysis 
The genetic analyses were done on genomic DNA extracted from white blood cells (6). 
Genotyping of rs72613567 was performed using a custom TaqMan genotyping assay (see 
Supplemental information) (Applied Biosystems, California 92008, USA) according to 
manufacturer’s instructions, and confirmed by DNA Sanger Sequencing (Macrogen, Inc., 













South Korea) (see Supplemental information and Supplemental Figure S1). Genotyping of 
the PNPLA3 rs738409 was performed as previously described (6).  
To ensure genotyping quality, we included DNA samples as internal controls, hidden samples 
of known genotype, and negative controls (water). The overall genotype completion rate was 
100%. To account for possible population stratification, we used a collection of 13 SNPs at 
different loci (located in chromosomes 4, 15, 17, 13, 1, and 3) and then analyzed the data 
with the Structure program Version 2 (14) as we explained elsewhere (6;15;16). We found no 
evidence of stratification in our sample because the cases and the controls showed similar Q 
values and the Structure program assigned a similar distance to clusters with no further 
improvement in the fitting model by adding up to four clusters (the ln of likelihood was 
maximum for K = 1).  
Using the CaTS power calculator for genetic association studies  (17) and assuming a 
prevalence of NAFLD of 0.30, minor allele frequency (MAF) A-INS 0.16 (the frequency 
found in our population, 0.84 for the risk allele), and an odds ratio (OR) of 1.8/0.56, our 
sample had 83% and 99%, for the additive and multiplicative genetic model, respectively.  
Liver immunohistochemistry (IHQ) 
Four-micrometer sections were mounted onto silane coated glass slides to ensure section 
adhesion through subsequent staining procedures. Briefly, sections were deparaffinized, 
rehydrated, washed in phosphate buffer solution (PBS), and treated with 3 % H2O2 in PBS for 
20 min at room temperature to block endogenous peroxidase. Following microwave heat-
induced epitope retrieval in 0.1M citrate buffer at pH 6.0 for 20 min, the slides were 
incubated with a dilution of 1:150 of rabbit polyclonal antibody for human anti-HSD17B13 
(HSD17B13 Antibody (OAAN01691) Size 50UL, Aviva Systems Biology, San Diego, CA 
92121 USA). Immunostaining was performed using the VECTASTAIN Elite ABC Kit 
(Vector Lab. CA, USA) detection system. Subsequently, slides were immersed in a 0.05%
 













3,3'-diaminobenzidine solution in 0.1 M Tris buffer, pH 7.2,
 
containing 0.01 % H2O2. After a 
brown color developed, slides were removed and the reaction was stopped by immersion in 
PBS. Negative controls were carried out with rabbit serum diluted to the same concentration 
as the primary antibody. HSD17B13 immunostaining was evaluated in a blinded fashion 
regarding any of the histological and clinical characteristics of the patients. The extent of 
staining was scored according to its amount and intensity by a 4-point scoring system as 
follows: 0 = no staining, 1 = positive staining in less than 20% of cells, 2 = 21-50 % of 
positive cells, and 3 = positive staining in more than 50% of cells. Histological specimens 
were assessed by a LEICA DM 2000 (Leica, Germany) trinocular microscope equipped with 
a high-definition camera (Leica MC190 HD); all images were recorded using the Leica 
Application Suite (LAS) software. 
Gene expression profiling of the liver transcriptome 
Total RNA was prepared from fresh liver tissue using phenol extraction step method, with an 
additional DNAse digestion. After extraction, RNA quantity was measured using the ND-
1000 spectrophoto meter (NanoDrop Technologies, Wilmington, USA), the ratio of 
absorbance 260 nm/280 nm being 1.9-2.0. 
For NAFLD patients carrying the rs72613567 (-/-) homozygous genotype (n = 8), one target 
for each sample was prepared. For the reference group (rs72613567-A/A homozygous 
genotype), pooled samples from 5 patients were used. Same proportion of NASH and NAFL 
patients were included per rs72613567-genotype group; selection of cases was based on the 
availability of RNA of sufficient quality and quantity to perform the microarray experiment.   
Samples were further processed using the SurePrint G3 Unrestricted Gene Expression 8x60K 
Microarray (product number G4140-90050; Agilent Santa Clara, CA 95051, United States) 
according to instructions provided by the manufacturer. This array allows the testing of 
26,083 Entrez Genes and 30,606 long noncoding RNAs (lncRNAs). The cDNA (cRNA) 













synthesis involved a single amplification, for two color labeling; probes from rs72613567 (-/-
) tissue and from the reference tissue (rs72613567 A/A) were differentially labeled by the 
incorporation of cyanine 3 (Cy3) and cyanine 5 (Cy5), respectively. Feature extraction, 
quantification of the intensity of fluorescent images, and scanned images were processed and 
analyzed by Agilent SureScan Microarray Scanner Bundle, Agilent Scan control software, 
and Agilent GeneSpring 14.5-GX software, respectively. We used fold change (FC) values 
generated by the software from the array data as the ratio of Lowess normalized, background 
subtracted Cy5/Cy3 signals if they passed the built-in QC analysis of the software executed 
according to the manufacturer’s protocol for two-color experiments. Linearization of the data 
was undertaken by log2 transformation. 
Gene enrichment analysis 
In addition to the liver whole-genome expression exploration we conducted gene set 
enrichment analysis to investigate the pathways and biological processes potentially 
associated with the differentially expressed genes. FunRich v.3.1.3 (http://www.funrich.org) 
software was used; only pathways that reached significant threshold were considered.    
Statistical analysis 
Quantitative data are expressed as mean ± standard deviation (SD) unless otherwise 
indicated. As a significant difference in SD was observed between the groups in most of the 
variables and the distribution was significantly skewed in most cases, we chose to be 
conservative and assessed the differences between the groups using nonparametric Mann–
Whitney U or Kruskal-Wallis tests. The Cochran–Armitage test for trend was used in the 
categorical data analysis to assess the presence of association between the variant and the 
disease severity, as well as histological outcomes; chi-square (χ
2
), odds ratio (OR), and p 
value are informed. Ordinal variables were dichotomized as ballooning degeneration, lobular 
inflammation, and liver fibrosis: yes (1)/ no (0). In addition, we used generalized linear and 













non-linear models (logistic regression and ANCOVA using binomial or ordinal multinomial 
distribution with logit and probit as link functions, respectively), adjusting for co-variables, 
which were log-transformed. Then, adjustment for potential demographic, clinical, and 
genetic confounders (rs738409) was also performed. The CSS/Statistica program package 
version 6.0 (StatSoft, Tulsa, OK, USA) was used in these analyses.  
RESULTS 
Clinical, biochemical, and histological features of patients with histological confirmation of 
NAFLD are shown in Table 1. While the studied population primarily comprised of patients 
with NAFLD and features of the MetS, the cohort also included 88 morbidly obese persons 
who represented 24.7% of the total sample. The control group characteristics are shown in 
Supplemental Table S1.  
Genotype frequencies of rs72613567 (-/-: 436, -/A: 152, A/A: 21, p = NS) were in Hardy-
Weinberg equilibrium (HWE); the frequency of the rs72613567 A-INS allele in our sample 
was 16%. Clinical, biochemical, and histological characteristics of the studied population 
according to rs72613567 genotypes are shown in Table 2. Significant differences in the body 
mass index (BMI) were observed between homozygous carriers (-/-) and those homozygous 
for the A-INS allele (A/A). Therefore, covariates that were significant in the univariate 
analysis were included in our logistic regression model. In further association analyses 
between disease-related binary outcomes (present/absent) and rs72613567 genotypes, BMI 
was systematically assessed as independent variable.  
We found no interaction effect between the rs72613567 and PNPLA3-rs738409. 
Nevertheless, this result should be considered with caution because the sample size employed 
in our study did not allow sub-stratification of the population according to the different 
genotypes (nine combinations) with sufficient power to detect interactions.  













Findings yielded by our additive model of inheritance indicate that the rs72613567 variant is 
associated with reduced odds of having NAFLD (OR per A-INS allele: 0.667, 95% CI 
0.486−0.916, p = 0.012). However, the protective effect of the rs72613567 variant on 
NAFLD was not significant (p = 0.076) when BMI was included in the logistic regression 
analysis.  
The presence of the rs72613567 A-INS allele is associated with a protective effect against 
severe NAFLD- histological features 
The results of genotypic Cochran-Armitage test for trend revealed a significant association of 
the rs72613567 and disease severity. The rs72613567 A-INS allele was associated with lower 
odds of having NASH (χ
2
 = 5.169, p = 0.023, cumulative OR: 0.568, 95% CI 0.350−0.922, 
NASH versus NAFL) (Figure 1, a). Logistic regression analysis showed that the association 
of the rs72613567 variant and the histological disease severity was independent of BMI (p = 
0.033, OR per A-INS allele: 0.612, 95% CI 0.388−0.964).  
In addition, presence of the rs72613567 A-INS allele was associated with a protective effect 
against severe histological outcomes, including ballooning degeneration (χ
2
 = 6.758, p = 
0.009, cumulative OR: 0.461, 95% CI 0.262−0.813) and lobular inflammation (χ
2
 = 11.444, p 
= 0.001, cumulative OR: 0.383, 95% CI 0.217−0.674), according to the results yielded by the 
Cochran-Armitage test for trend. Protective associations of the rs72613567 variant and 
ballooning degeneration (p = 0.010, OR-per A-INS allele: 0.474, 95% CI 0.267−0.842) and 
lobular inflammation (p = 0.0074, OR-per A-INS allele: 0.475, 95% CI 0.275−0.821) were 
independent of BMI.   
Likewise, carrying the rs72613567 A-INS allele reduced the likelihood of developing liver 
fibrosis (χ
2
 = 4.323, p = 0.038, cumulative OR: 0.567, 95% CI 0.334−0.961). This protective 
effect against fibrosis was found to be independent of BMI (p = 0.035, OR-per A-INS allele: 
0.590, 95% CI 0.361−0.965). 













The rs72613567 A-INS allele was significantly associated with lower NAS scores (NAS 
score < 5 vs. NAS score ≥ 5), χ
2
 = 9.249, p = 0.002, cumulative OR: 0.338, 95% CI 
0.171−0.668. This effect was also independent of BMI (p = 0.024, OR-per A-INS allele: 
0.369, 95% CI 0.154−0.886). The degree of liver steatosis, as evaluated by liver biopsy and 
expressed as a percentage of hepatocytes infiltrated by fat, was not associated with the 
rs72613567 variant.  
Finally, the rs72613567-A-INS allele was associated with lower levels of serum ALT (p = 
0.025) and AST (p = 0.044); however, this association was specifically found in the dominant 
model of inheritance (-/- vs. -/A + A/A) (Figure 1, b).  
Logistic regression analysis showed that the rs72613567 variant remains significantly 
associated with the disease severity and liver damage-related histological outcomes 
(ballooning degeneration, fibrosis, and lobular inflammation) after adjusting for potential 
demographic, clinical, and genetic confounders in addition to BMI (Table 3).  
HSD17B13 protein expression is significantly decreased in the liver of patients with 
NAFLD carrying the rs72613567 A-INS allele 
In a recent study, Abul-Husn et al. used RNA sequencing to discover the functional effects of 
the rs72613567 splice variant. The authors reported that the rs72613567 A-INS allele was 
associated with a premature truncation of the protein (9).  
By using IHQ expression in the liver of patients with NAFLD, we explored the level of 
HSD17B13 according to the rs72613567 genotypes (Figure 2, a-b). We found significantly 
lower levels of HSD17B13 protein in the liver of patients carrying the A-INS allele compared 
with patients homozygous for the deletion (-/-) (Figure 2, a-b). HSD17B13 
immunoreactivity product was significantly reduced in an allele dose-dependent manner 
(linear test for trend p < 0.0001, slope -0.993). Moreover, statistical analysis revealed 
significantly reduced HSD17B13 immunoreactivity in subjects carrying at least one copy of 













the rs72613567 A-INS allele compared to that noted in homozygous -/- patients (p = 0.0003, 
Mann–Whitney test). We observed selective HSD17B13 immunoreactivity within the 
hepatocytes, but not other cell types of the liver; analysis of subcellular localisation of 
HSD17B13 showed immunoreactivity primarily associated to cytoplasmic elements, 
including membrane-bounded organelles and small lipid droplets (Figure 2, c). We also 
observed robust immunostaining in the vicinity of the hepatocyte membrane, which is a 
potentially novel feature (Figure 2, c).  
Liver gene expression profiling according to rs72613567 genotypes suggests differences in 
immune mediated pathways  
We hypothesised that rs72613567 could be associated with patterns of intrahepatic gene 
expression that explain the impact of the variant on the phenotype. Transcriptome analysis 
revealed differential expression of 161 genes. The most (≥3.5-fold) down-regulated and up-
regulated genes in the liver of patients carrying the rs72613567 (-/-) genotype relative to the 
expression levels of patients homozygous for the A-INS allele are illustrated Figure 3, a, 
while the entire gene list, including fold changes and p values, is shown in Supplemental 
Table S2. These results provide valuable insight into the putative global transcriptional 
response associated with the variant, which seems to be significantly enriched by biological 
pathways related to the immune system, including antigen presentation and interferon-related 
processes, cytokine signalling, and signal transduction (Figure 3, b). In addition, enrichment 
analysis findings indicate that the ―SRP-dependent cotranslational protein targeting to 
membrane‖ pathway is significantly overrepresented (Figure 3, b). This pathway involves a 
cytosolic signal recognition particle (SRP) to form a complex, which in turn docks with an 
SRP receptor complex on the endoplasmic reticulum membrane 
(https://reactome.org/content/detail/R-HSA-1799339).  
DISCUSSION 













As a part of the present study, we found that the rs72613567 variant in HSD17B13 gene 
confers protection against NAFLD severe histological disease. In line with the recent seminal 
findings reported by Abul-Husn and coworkers (9), we observed that the rs72613567 A-INS 
allele is associated with decreased risk of chronic liver damage in NAFLD patients, 
specifically with a ~40% reduction in the odds of developing NASH. In addition, by 
exploring the association between the variant and histological outcomes of liver injury, we 
found a protective effect of the rs72613567 A-INS allele against ballooning degeneration, 
lobular inflammation, and liver fibrosis. In patients carrying the rs72613567 A-INS allele, the 
odds (per allele) of presenting ballooning degeneration and lobular inflammation are 50% 
lower relative to those pertaining to patients who do not carry the insertion allele. 
Furthermore, presence of the rs72613567 A-INS allele reduces the risk of liver fibrosis by 
~40% per allele. In addition, in agreement with recently published evidence (9), we observed 
that rs72613567 was associated with serum levels of transaminases in the dominant model of 
inheritance.  
In the present study, we not only replicated the findings of Abul-Husn et al. (9), but also 
provided novel information regarding the protective effect of the variant against histological 
features associated with progressive liver disease. In our sample, we observed that all 
significant associations with histological traits remained independent of BMI. On the 
contrary, the variant does not seem to robustly influence the susceptibility of fatty liver, as 
the effect remained non-significant when BMI was included in the logistic regression model. 
Hence, these results suggest that the effects of rs72613567 on NAFLD pathogenesis are 
restricted to the cellular events associated with liver damage, rather than pertaining to those 
mediating fat accumulation in the hepatocyte. This observation is in agreement with the 
results of Abul-Husn et al. that originally found the lack of association between the variant 
and NAFLD as disease trait (9). 













However, a key aspect of the Abul-Husn et al. paper (9) and the current study is that in both 
studies the effect of the variant is considerably large (odds ratios approaching 0.5). This is 
substantially important for a complex trait like liver fibrosis.   
The frequency of the rs72613567 A-INS allele in our sample was 16%, which is in line with 
that reported in the 1000 Genomes Project for the A-INS allele in American Population (1000 
Genomes Project, Phase 3, http://www.ensembl.org). However, this percentage is lower than 
that observed in European Americans (9). Regarding ethnicity, our sample of patients and 
controls might present both similarities and differences compared with the sample included in 
the study of Abul-Husn et al. (9). In fact, our sample is composed of subjects of self-reported 
European ancestry. Nevertheless, we cannot rule out the influence of other factors, including 
recombination events, different degrees of genetic diversity and linkage disequilibrium 
patterns, and environmental exposure, which together may suggest that our cohort could be 
regarded as a distinctive one compared to the sample of Abul-Husn et al.(9). Hence, one may 
a priori speculate that our replication study might support the generalizability of the seminal 
results (9).   
Frequency diversity of rs72613567 across different populations might potentially explain 
differences in prevalence and severity rates of NAFLD across ethnic groups. Nevertheless, 
this conclusion needs extensive validation because the role of the rs72613567 variant in the 
protection against NASH has not been extensively explored.  
Earlier functional exploration of rs72613567 has robustly demonstrated that the splice variant 
associates with liver transcripts that encode a prematurely truncated HSD17B13 protein (9). 
Hence, it is postulated that the rs72613567 variant mediates its protective effect(s) against 
severe liver damage by disrupting HSD17B13 protein expression. Our results consistently 
showed that the rs72613567 A-INS allele is significantly associated with decreased levels (or 













absence) of HSD17B13 protein in the liver of heterozygous (-/A) and homozygous (A/A) 
patients with NAFLD, respectively, in an allele dose-dependent manner.  
Whereas there is reproducible information regarding tissue-expression patterns of HSD17B13 
protein (9;10), including the findings reported by Horiguchi et al. who demonstrated a 
predominant tissue distribution of HSD17B13 in the liver compared to the intestine (11), 
knowledge of the actual function and regulation of the HSD17B13 gene is relatively limited. 
The protein encoded by HSD17B13 belongs to the short-chain dehydrogenases/reductases 
(SDR) family, which is involved in the metabolism of steroid hormones, prostaglandins, 
lipids, xenobiotics and retinoids (18). Lipid-particle organisation and regulation of lipid 
biosynthesis are principal biological processes associated with HSD17B13 protein activity 
(10;11).  
We confirmed the subcellular localisation of HSD17B13 in the liver of patients with NAFLD, 
which was primarily observed in the cytoplasm of hepatocytes in close association with the 
surface of small fat droplets and the cell membrane facing adjacent hepatocytes (Figure 2, b-
c). Furthermore, HSD17B13 expression was found to be negative in other cellular 
components of the liver tissue milieu, including inflammatory cells, vascular or bile ductular 
cells (Figure 2, b-c). One might speculate that the differential expression of the HSD17B13 
protein on the surface of liver lipid droplets (LD) (9-11;19) may help explain associations 
with the phenotype. In fact, there is robust evidence indicating that liver LDs are 
multifunctional organelles, which are not only associated with other cellular structures, 
including endoplasmic reticulum, but also recruit cytosolic proteins and inflammatory 
mediators (20).  
As shown by Zhang et al. who evaluated the preferential distribution of proteins according to 
different subpopulations of LDs, small LDs are enriched of members of small molecular 













weight GTPases (known as small G-proteins) (20), which are involved in important cellular 
processes, including cell proliferation, cytoskeletal dynamics and vesicle transport (21).  
The interpretation of protein localization should be taken with caution because we cannot rule 
out the probability of HSD17B13 can localize to other organelles, including vesicles or 
lysosomes.  
We have investigated the relationship between the rs72613567 genotypes and liver gene 
expression patterns. We found an overrepresentation of pathways associated with the immune 
response, including antigen processing and interferon gamma mediated signalling pathways, 
which resembles inflammatory response of the autoimmune diseases.  
It should be noted, however, that these results were derived from a comparison of a small 
sample of patients that presented severe NAFLD histological disease and the rs72613567 (-/-) 
genotype with patients with less severe NAFLD and the rs72613567 (A/A) genotype. Thus, it 
could be argued that the transcriptional landscape could reflect changes associated with the 
disease severity per se rather than the rs72613567 genotypes. Nonetheless, we carefully 
balanced the proportion of patients with severe histological disease that were included in the 
analysis per genotype. 
On the other hand, results from animal studies, particularly Hsd17b13-knockout (KO) mice, 
suggest a contrasting scenario (22) to that of observed in human studies. Hsd17b13-KO mice 
show increased hepatic de novo lipogenesis and are prone to develop severe NAFLD with 
portal inflammation (22). Hsd17b13-KO mice are neither obese nor insulin resistant but 
present overexpression of proteins involved in fatty acid synthesis (22). It thus seems difficult 
to translate the experimental results noted above to humans, particularly because the genetic 
component of NAFLD is very much dependent on the interaction between genetic modifiers 
and environmental factors. Likewise, moderate interspecies homology in members of the 













17β-HSD (hydroxysteroid dehydrogenases) family (23) might explain difficulties in 
explaining results based on animal models.    
Although our work provides insights on the effect of the rs72613567 variant in mitigating the 
chances of having NASH, it has some limitations. For example, we cannot draw broader 
conclusions about the role of the variant in protection against end-stage liver disease, 
including cirrhosis and hepatocellular carcinoma. In addition, our population did not include 
a representative sample of lean patients with NAFLD, in whom the role of the variant in 
protecting against severe histological outcomes requires specific validation. 
In conclusion, the presence of the rs72613567 A-INS allele mitigates the prevalence of 
NASH, as well as the severity of histological lesions, in patients with NAFLD in our 
population. The phenotypic variance of NAFLD seems to be largely influenced by common 
(frequent) genetic variation in loci that regulate lipid metabolism and liver lipid droplet 
plasticity and dynamics in high interaction with the environment. It thus seems reasonable to 
presume that NAFLD pathogenesis is not limited to excessive fat deposition but also depends 
on how hepatocytes deal with excesses of lipids/fatty acids.  
Findings regarding the protective effect of the rs72613567 A-INS allele on severe 
histological disease might predictably have impact on NAFLD diagnosis and management. 
For example, knowledge of patient’s genotype might be useful for biomarker discovery and 
subject stratification in clinical trials, and may lead to more precise treatment decisions, 
especially when using novel drugs. Moreover, a comprehensive druggability assessment of 
HSD17B13 protein, including therapeutic gene inhibition by silencing strategies or use of 
small molecules for selective HSD17B13 enzyme inhibition, would be of remarkable impact 
in the translational field. 
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Table 1: Clinical and biochemical features of patients with NAFLD according to the 
disease severity   
Variables NAFL NASH p value 
Number of subjects (%) 165 (46)  191 (54)  
Female, %  59.4 65 NS 
Age, years 49.5±12 50.5±12 NS 
BMI, kg/m
2
 38.3±13 36.5±9.4 NS 
Arterial hypertension, % 41.6% 51.3% NS 
Glucose-related profile  
Fasting plasma glucose, mg/dL 100±25 129±110 1.0 x 10
-8 
Fasting plasma insulin, μU/ml 13.3±8.8 19±20 1.0 x 10
-8 
HOMA-IR index 3.34±2.5 6.6±16 1.0 x 10
-8 
HbA1c 6.3±1.3 7.5±4.4 NS 
Type 2 diabetes, % 29 51.3 0.000038 
Lipid profile 
Total cholesterol, mg/dL 199±50 204±46 NS 
HDL-cholesterol, mg/dL 49.5±21 48±14 NS 
LDL-cholesterol, mg/dL 125±44 125±42 NS 
Triglycerides, mg/dL 157±88 187±115 0.059 
Uric acid, mg/dL 5.6±7.5 5.0±2.0 NS 
Liver phenotype 
ALT, U/L 49±53 70±55 1.0 x 10
-8 
AST, U/L 32±17 49±33 1.0 x 10
-8 
GGT, U/L 67±57 88±96 0.098 
AP, U/L 183±113 202±115 0.098 
Histological Features of NAFLD 
Degree of steatosis (0-3) 1.85±0.81 2.4±0.75 0.000068 
Lobular inflammation (0-3)  0.52±0.61 1.33±0.68 1.0 x 10
-8 
Hepatocellular ballooning (0-2) 0.09±0.28 0.87±0.60 1.0 x 10
-8 
Fibrosis Stage  0.06±0.33 1.6±0.70 1.0 x 10
-8 
NAFLD activity score (NAS) 2.4±1.20 4.5±1.2 1.0 x 10
-8 
 
NAFLD: nonalcoholic fatty liver disease; NAFL: nonalcoholic fatty liver; NASH: 
nonalcoholic steatohepatitis; BMI: body mass index; HOMA: homeostatic model assessment; 
HbA1c: glycated haemoglobin; ALT and AST: Serum alanine and aspartate 
aminotransferase. GGT: gamma-glutamyl-transferase; AP: alkaline phosphatase. Results are 
expressed as mean±SD. P value stands for statistical significance using Mann-Whitney U 
test, except for female/male proportion, arterial hypertension, and type 2 diabetes that p 
values stand for statistical significance using Chi-square test.   













Table 2: Clinical and biochemical features of subjects included in the study according to 
the rs72613567 genotypes 
Variables rs72613567 (-/-) rs72613567 (-/A) 
 
rs72613567 (A/A) 
Number of subjects (%) 436 152 21 
Female, %  63.5 65.3 66 
Age, years 49±13 49±13 48±12 
BMI, kg/m
2
 35±11.5 34±12 30±10 ** 
Glucose-related profile  
Fasting plasma glucose, mg/dL 106±46 100±33 95±22
 
Fasting plasma insulin, μU/ml 14±15 12±10 11±7.5 
HOMA-IR index 4±10 3±3.4 2.7±3
 
HbA1c 7±3 6.3±1.3 5±1.4 
Lipid profile 
Total cholesterol, mg/dL 203±48 194±50 210±41 
HDL-cholesterol, mg/dL 49±17 48±17 48±22 
LDL-cholesterol, mg/dL 126±43 120±45 121±50 
Triglycerides, mg/dL 162±101 145±89 173±90 
Liver phenotype 
ALT, U/L 53±54 42±38 * 38±35
 
AST, U/L 37±28 31±19 * 32±18 
GGT, U/L 65±72 68±99 75±119 
AP, U/L 183±111 171±104 193±127 
 
BMI: body mass index; HOMA: homeostatic model assessment; HbA1c: glycated 
haemoglobin; ALT and AST: Serum alanine and aspartate aminotransferase. GGT: gamma-
glutamyl-transferase; AP: alkaline phosphatase. Results are expressed as mean±SD. P value 
stands for statistical significance using Mann-Whitney U test, except for female/male 
proportion that p values (<0.01) stand for statistical significance using Chi-square test.  
* Indicates rs72613567 (-/-) vs. rs72613567 (-/A); ** indicates rs72613567 (-/-) vs. 
rs72613567 (A/A).   
 
 













Table 3: Association analysis of rs72613567 after adjustment for potential confounding 
variables  
Trait OR (95% CI) P value 
Disease severity  0.635 (0.404-0.9990 0.049 
Ballooning degeneration 0.468 (0.278-0.817) 0.007 
Lobular inflammation 0.450 (0.263-0.770) 0.003 
Fibrosis 0.416 (0.174-0.997) 0.048 
 
Potential confounding variables: sex, age, BMI (body mass index), HOMA-IR and rs738409 
(PNPLA3); p value and OR stand for statistical significance an odds ratio, respectively, using 
analysis in logistic regression model.  BMI and HOMA-IR were log-transformed. 














Figure 1: Association of HSD17B13 rs72613567 with NAFLD disease severity and 
aminotransferase levels 
 
Panel a shows distribution of rs72613567 genotypes according to the histological disease 
severity (NASH vs. NAFL). P value denotes statistical significance in the Cochran-Armitage 
test for trend (additive model of inheritance). NAFL: nonalcoholic fatty liver; NASH: 
nonalcoholic steatohepatitis. 
Panel b shows analysis of the association between rs72613567 genotypes and serum levels of 
ALT (alanine) and AST (aspartate) aminotransferases in the dominant model of inheritance (-
/- vs. -/A + A/A); statistical differences between groups were evaluated using Mann–Whitney 
U test. Bars express mean ± SE.  













Figure 2: Expression and subcellular localisation of HSD17B13 protein in the liver   
Panel a shows the scores of HSD17B13 expression in patients with NAFLD evaluated by 
immunohistochemistry according to rs72613567 genotypes (-/- n = 8, -/A n = 7, A/A n = 5). 
Values represented by vertical bars are mean ± SD; mean values of HSD17B13 
immunoreactivity in the liver of rs72613567 homozygous A/A, heterozygous -/A, and 
homozygous -/- patients were compared by ANOVA and statistical differences between 
groups were evaluated using Neuman-Keuls test. ANOVA post-test for linear trend was 
performed, and slope, R
2
, and p values are shown in the graph.  
Panel b shows representative liver expression pattern of HSD17B13 in NAFLD patients 
carrying the rs72613567 -/-, rs72613567 -/A, and rs72613567 A/A genotypes. Original 
magnification: 200×.  
Panel c shows patterns of subcellular localisation of HSD17B13 in representative NAFLD 
patients carrying the rs72613567 -/- homozygous genotype. The asterisks indicate the inset 
(4× amplification of the original image) showing that the protein presents exclusively 
cytoplasmic immunoreactivity, which preferentially accumulates on the surface of small fat 
droplets (arrow) or close to the hepatocyte membrane (arrow). HSD17B13 immunoreactivity 
was examined using light microscopy of liver sections. Original magnification 400×. LD: 
lipid droplets and PT: portal tract. 
 













Figure 3: Liver whole gene expression profiling and pathway enrichment analysis in 
patients with NAFLD according to rs72613567 genotypes    
 
Panel a shows fold change of up-regulated and down-regulated genes in the liver of patients 
carrying the rs72613567 (-/-) genotype considering as reference the expression of the whole 
transcriptome in the liver of patients carrying two copies of the rs72613567 A-INS allele.  
The most (≥ 3.5-fold) down-regulated and up-regulated genes that reached statistical 
significance after multiple testing correction are illustrated on the charts. The entire list of 
genes is shown in Supplementary Table S2.  
CFH: complement factor H; FGL1: fibrinogen-like 1; HBB: hemoglobin, beta; SERPINC1: 
serpin peptidase inhibitor, clade C (antithrombin) member 1; TOMM7: translocase of outer 
mitochondrial membrane 7 homolog (yeast); HBD: hemoglobin, delta; UBD: ubiquitin D; 
ACTA1: actin, alpha 1, skeletal muscle; PSPH: phosphoserine phosphatase; EEF1A1: 
eukaryotic translation elongation factor 1 alpha 1. SCGB3A1: secretoglobin, family 3A, 
member 1; LINC01197: long intergenic non-protein coding RNA 1197; MMACHC: 
methylmalonic aciduria (cobalamin deficiency) cblC type, with homocystinuria; TMSB4X: 
thymosin beta 4, X-linked; MON1B: MON1 secretory trafficking family member B; 
CRYBB2P1: crystallin, beta B2 pseudogene 1; ID4: inhibitor of DNA binding 4, dominant 
negative helix-loop-helix protein; MUC5AC: mucin 5AC, oligomeric mucus/gel-forming; 
RPL32: ribosomal protein L32; FAM212A: family with sequence similarity 212, member A; 
WIPF3: WAS/WASL interacting protein family, member 3; MSTO1: misato 1, mitochondrial 
distribution and morphology regulator; LINC01488: long intergenic non-protein coding RNA 
1488; TEKT4P2: tektin 4 pseudogene 2; GNG13: guanine nucleotide binding protein (G 
protein), gamma 13; FAT3: FAT atypical cadherin 3; ANP32A-IT1: ANP32A intronic 
transcript 1 (non-protein coding). 
Panel b shows gene enrichment analysis for biological processes (Gene Ontology database) 
using the FunRich (http://www.funrich.org) tool. Bonferroni and Benjamini-Hochberg and 
FDR (false discovery rate) method were used to correct for multiple testing. 
Pathways were ranked according to the p value (red bar); a p value lower than 0.05 was 
considered significant. The blue bar indicated the percentage of altered genes in a whole 
pathway. 
 
















 by guest, on N
ovem
ber 13, 2018
w
w
w
.jlr.org
D
ow
nloaded from
 
